Drug class
Antineoplastic aminoacridine derivative
Mechanism of action
Its mechanism is incompletely defined; available pharmacology describes DNA intercalation and inhibition of topoisomerase II, leading to DNA damage and tumour-cell death.
General use cases
- Acute leukaemia (reported clinical-use context; current authorisation and use are jurisdiction- and product-specific)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
